We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
+14.86%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$366M
AUM Growth
+$56.4M
Cap. Flow
+$27.5M
Cap. Flow %
7.51%
Top 10 Hldgs %
57.01%
Holding
57
New
4
Increased
13
Reduced
4
Closed
5

Top Buys

Rank Stock Value
1
CCXI
ChemoCentryx, Inc.
CCXI
+$13.3M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$8.76M
3
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$8.6M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$7.46M
5
AMGN icon
Amgen
AMGN
+$6.46M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$19.1M
2
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$8.98M
3
IMMU
Immunomedics Inc
IMMU
+$4.22M
4
IOVA icon
Iovance Biotherapeutics
IOVA
+$3.45M
5
BIIB icon
Biogen
BIIB
+$2.79M

Sector Composition

Rank Sector Weight
1 Healthcare 99.56%
2 Miscellaneous 0.44%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZEAL
51
DELISTED
Zealand Pharma A/S American Depositary Shares
ZEAL
$203K 0.06%
5,653
– –
CYTK icon
52
Cytokinetics
CYTK
$10.8B
– –
-25,000
Closed -$541K
IMUX icon
53
Immunic
IMUX
$222M
– –
-12,300
Closed -$2.28M
ARNA
54
DELISTED
Arena Pharmaceuticals Inc
ARNA
– –
-16,500
Closed -$1.23M
MYOK
55
DELISTED
MyoKardia, Inc. Common Stock
MYOK
– –
-65,859
Closed -$8.98M
IMMU
56
DELISTED
Immunomedics Inc
IMMU
– –
-49,700
Closed -$4.22M
1 2
3

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q4 2020 Portfolio in Review

As of Q4 2020, International Biotechnology Trust held 57 positions worth $366M, up 18% from $310M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

International Biotechnology Trust deployed $27.5M of net new capital in Q4 2020, opening 4 new positions and adding to 13 existing holdings. Its largest new stake was Oric Pharmaceuticals: 53,000 shares worth $1.79M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Neurocrine Biosciences, an estimated $19.1M trimmed.

  • International Biotechnology Trust's largest Q4 2020 buy was Oric Pharmaceuticals: 53,000 shares worth $1.79M.
  • International Biotechnology Trust added most to ChemoCentryx, Inc. in Q4 2020, an estimated $13.3M increase.
  • International Biotechnology Trust's biggest Q4 2020 reduction was Neurocrine Biosciences, cutting an estimated $19.1M.
  • International Biotechnology Trust fully exited MyoKardia, Inc. Common Stock in Q4 2020, selling an estimated $8.98M.
  • International Biotechnology Trust's ten largest holdings make up 57% of its $366M portfolio in Q4 2020.
  • International Biotechnology Trust opened 4 new positions and closed 5 in Q4 2020.
  • International Biotechnology Trust's portfolio value rose 18% quarter-over-quarter to $366M.

Based on International Biotechnology Trust's 13F filing for Q4 2020, filed 19 Feb 2021.